TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10363611
Drug: Heparin-coated circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuits ('Bioline' by Jostra)
Study: 7669486
Drug: Remoxipride 50
Normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride 50 mg
Study: 7669486
Drug: Thyrotropin release
Normalized name: Thyrotropin
DrugBank: Thyrotropin (DB15263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin release hormone (TRH)
Study: 340945
Drug: terbutaline 2.5
Normalized name: terbutaline 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terbutaline 2.5 mg
Study: 340945
Drug: aminophylline 200
Normalized name: aminophylline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aminophylline 200 mg
Study: 340945
Drug: terbutaline 2.5
Normalized name: terbutaline 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terbutaline 2.5 mg plus aminophylline 200 mg
Study: 21886067
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg bid, Amoxicillin 1 g bid, Clarithromycin 500 mg bid (LAC) for 14 days
Study: 21886067
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg bid, Levofloxacin 500 mg bid, Amoxicillin 1 g bid (OLA) for 7 days
Study: 12567694
Drug: Benflumetol tablet
DrugBank: Lumefantrine (DB06708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benflumetol tablet
Study: 12567694
Drug: Benflumetol capsule
DrugBank: Lumefantrine (DB06708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benflumetol capsule
Study: 25524333
Drug: Prasugrel pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel pre-treatment (30-mg loading dose)
Study: 15359898
Drug: Pravastatin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin therapy
Study: 11207518
Drug: 5-day RACM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day RACM regimen (rabeprazole 20 mg b.d., amoxicillin 750 mg b.d., clarithromycin 200 mg b.d., metronidazole 250 mg b.d.)
Study: 8341175
Drug: Carbimazole 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbimazole 15 mg twice daily (group 2)
Study: 8341175
Drug: Carbimazole 10
Normalized name: carbimazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbimazole 10 mg thrice daily (group 3)
Study: 9060552
Drug: no initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: no initial treatment
Study: 17363538
Drug: Indisulam (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indisulam (700 mg/m2 as a single i.v. dose on day one)
Study: 17363538
Drug: Indisulam (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indisulam (130 mg/m2 given on days 1 to 5 as a daily infusion)
Study: 17363538
Drug: Indisulam (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indisulam (both treatment schedules)
Study: 11132373
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg elemental iron twice-weekly for 12 months
Study: 16645456
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia
Study: 18485457
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (Control)
Study: 20865580
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received standard anesthetic protocol and IV morphine via PCA
Study: 16642606
Drug: Spray inhalation
Normalized name: Inhalation Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray inhalation of western medicine, once daily for 7 days.
Study: 23055414
Drug: Paroxetine (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20-40 mg) with mirtazapine
Study: 23055414
Drug: Paroxetine (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20-40 mg) with placebo
Study: 16935794
Drug: 5% Vitreoscilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Vitreoscilla filiformis (V.f.) extract-containing ointment
Study: 18390083
Drug: Oral medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medroxyprogesterone acetate (5 mg daily)
Study: 29234748
Drug: Calcium‐incorporated titanium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium‐incorporated titanium implants (Xpeed)
Study: 26355169
Drug: Control resorbable
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control resorbable blasted media (RBM) implants
Study: 21673005
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg on alternate days
Study: 22090661
Drug: Prediction-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction-based treatment using the newly developed model
Study: 22090661
Drug: Selective treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective treatment of women >65 years of age
Study: 22090661
Drug: Aspirin treatment
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin treatment strategy
Study: 19673814
Drug: music-supported therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: music-supported therapy
Study: 30834280
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional therapy (control group)
Study: 15057737
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg/day for 56 days
Study: 9673781
Drug: Inhaled HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled HFA BDP (0.2 or 0.8 mg)
Study: 2502168
Drug: Ketamine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 1.5 mg kg‐1
Study: 28709470
Drug: Cognitive Bias
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Bias Modification (CBM) training with oxytocin administration
Study: 28709470
Drug: Placebo training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo training with oxytocin administration
Study: 22196062
Drug: 6% sevoflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% sevoflurane with 4 L/min O₂ for 3 minutes
Study: 22196062
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-sevoflurane) with 4 L/min O₂ alone
Study: 18676056
Drug: 20Gy of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20Gy of radiation in 2 weeks followed by two courses of chemotherapy (paclitaxel 180mg/m², cisplatin 45mg/m², ifosfamide 1000mg/m²)
Study: 18676056
Drug: Treatment related
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment related morbidity
Study: 17519056
Drug: Same-room treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same-room treatment
Study: 15189943
Drug: Drotrecogin alfa
Normalized name: Drotrecogin Alfa
DrugBank: Drotrecogin alfa (DB00055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drotrecogin alfa (activated) 24 micro g/kg/h, continuous IV infusion for 96 ± 1 h
Study: 11440912
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein intake (0.3 g/kg/day) with [(15)N]Spirulina platensis
Study: 9059200
Drug: Morphine 10
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 10 mg
Study: 7973475
Drug: MTX 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX 7.5 mg/week and CHLO 250 mg/day
Study: 18716531
Drug: Regular oral
Normalized name: infant formula,regular ORAL PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular oral analgesics
Study: 29676980
Drug: 10% HP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% HP gel (low viscosity)
Study: 29676980
Drug: 10% HP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% HP gel (medium viscosity)
Study: 29676980
Drug: 10% HP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% HP gel (high viscosity)
Study: 11949768
Drug: Temazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam (15 mg)
Study: 10463516
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine (ddI) 500 mg/d
Study: 10463516
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine (ddI) 750 mg/d
Study: 10357377
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) monotherapy
Study: 10463516
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with ddI/ZDV
Study: 10463516
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with zalcitabine/ZDV
Study: 9035703
Drug: Tazarotene gel
Normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene gel applied once daily
Study: 7201839
Drug: Dihydroergotoxine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotoxine (2 mg, three times a day)
Study: 22257126
Drug: Fluoxetine (n=157)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (n=157)
Study: 10859864
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml PCECV intradermally at two sites on days 0, 3, 7, and at one site on days 30 and 90
Study: 10859864
Drug: Purified Vero
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified Vero cell rabies vaccine (PVRV) administered similarly to Group 1
Study: 10859864
Drug: 1.0 ml
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml PCECV intramuscularly on days 0, 3, 7, 14, 30 and 90
Study: 1279214
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg terazosin
Study: 1279214
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg terazosin
Study: 29713249
Drug: Placebo (gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (gelatin capsules)
Study: 26959502
Drug: Mobile unit
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile unit laser photocoagulation treatment
Study: 26959502
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to outpatient eye clinic for follow-up treatment
Study: 22710865
Drug: Neopterin levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neopterin levels before induction chemotherapy (day 0) in patient group 1 (children with acute leukemia)
Study: 2634902
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg i.v.)
Study: 6786673
Drug: 0.25-0.5 microgram
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25-0.5 microgram oral 1,25-dihydroxy vitamin D3
Study: 28049262
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (110 mg BTPP) of black tea drink
Study: 28049262
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (220 mg BTPP) of black tea drink
Study: 28049262
Drug: Placebo drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drink (0 mg BTPP)
Study: 25977992
Drug: Levobupivacaine 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.125% + sufentanil 0.75 μg/mL
Study: 25977992
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% + sufentanil 0.75 μg/mL
Study: 22796450
Drug: Antithrombotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapy plus rectal insufflation of O(3)
Study: 22796450
Drug: Antithrombotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapy only
Study: 17353246
Drug: Fosfomycin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin (8 g)
Study: 2407581
Drug: Highest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest quartile of fasting insulin distribution
Study: 31834660
Drug: Immediate periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate periodontal therapy (one‐stage scaling and root planning, amoxicillin 500 mg, metronidazole 400 mg, oral hygiene instructions)
Study: 31834660
Drug: Delayed periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed periodontal therapy (control group)
Study: 12552210
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (100 microg)
Study: 19517674
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (morphine and fentanyl)
Study: 19087079
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral nifedipine tablet
Study: 8203837
Drug: Sparfloxacin (SPX)
DrugBank: Sparfloxacin (DB01208)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sparfloxacin (SPX) 400 mg on day 1 and 200 mg on days 2 to 8
Study: 3300178
Drug: Trimethoprim 300
Normalized name: trimethoprim 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim 300 mg daily
Study: 11979239
Drug: Large-volume epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Large-volume epinephrine injection (13-20 mL)
Study: 11979239
Drug: Small-volume epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Small-volume epinephrine injection (5-10 mL)
Study: 29888938
Drug: Hypnotic suggestion
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic suggestion for thought insertion
Study: 21828036
Drug: Mometasone furoate/formoterol
Normalized name: mometasone furoate/formoterol fumarate 100/5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone furoate/formoterol (MF/F) 100/10 μg b.i.d.
Study: 22334769
Drug: Formoterol (F)
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol (F) 10 μg
Study: 26086920
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg IVTA
Study: 18463518
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg IVTA
Study: 18463518
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg IVTA
Study: 12448658
Drug: Arm B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: 120 microg/m2 bryostatin-1 given as a 72 hour continuous infusion every 2 weeks
Study: 7852514
Drug: Oral pamidronate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pamidronate, 150 mg/day for at least 5 years
Study: 10390000
Drug: Oral pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pamidronate
Study: 2892450
Drug: Cetirizine 5
Normalized name: cetirizine 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 5 mg
Study: 25829456
Drug: TIMA (Texas
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIMA (Texas Implementation of Medication Algorithm)
Study: 20849715
Drug: Probiotics (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (0.25 g, twice daily)
Study: 2848432
Drug: RIT 4237
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, RIT-4385 strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIT 4237 live attenuated bovine rotavirus vaccine
Study: 27811070
Drug: Tiotropium 2.5
Normalized name: TIOTROPIUM 2.5MCG/ACTUAT 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 2.5 µg
Study: 10634336
Drug: Triple drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple drug (zidovudine, lamivudine, and indinavir)
Study: 10634336
Drug: Triple drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple drug cases
Study: 19950739
Drug: Midazolam 50
Normalized name: midazolam 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 50 microg/kg plus Dexamethasone 0.5 mg/kg
Study: 17307170
Drug: Asoprisnil 5
Normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asoprisnil 5 mg
Study: 31777761
Drug: Asoprisnil 10
Normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asoprisnil 10 mg
Study: 10331682
Drug: Right-sided amobarbital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right-sided amobarbital injection
Study: 8768841
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated estrogen (1.25 mg daily)
Study: 8768841
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (100 micrograms/day)
Study: 8768841
Drug: GHRH administration
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH administration after oral estrogens
Study: 7039841
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dose of methyldopa
Study: 7039841
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily dose of methyldopa
Study: 6124760
Drug: Biosynthetic human
Normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosynthetic human insulin (BHI)
Study: 27589542
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and inhaled nitric oxide (iNO)
Study: 20056373
Drug: Breast pumping
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast pumping 0.6h after drinking a 0.4g/kg dose of alcohol (pumped after group)
Study: 21677574
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg/d
Study: 10855852
Drug: Local-regional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local-regional therapy alone for patients with low TLI tumors
Study: 26632520
Drug: Methotrexate (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (25 mg/wk)
Study: 24650819
Drug: Alcohol (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (target dose: .08 mg/kg)
Study: 22770549
Drug: Amiodarone 300
Normalized name: amiodarone 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone 300 mg
Study: 19521294
Drug: Lidocaine 1.5
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.5 mg/kg
Study: 2582711
Drug: Ranitidine 50
Normalized name: ranitidine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 50 mg every 8 hours
Study: 8252888
Drug: Ranitidine 6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 6.25 mg/hr continuous infusion
Study: 2582711
Drug: Ranitidine 10
Normalized name: ranitidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 10 mg/hr continuous infusion
Study: 186417
Drug: No immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No immunotherapy (control group).
Study: 186417
Drug: Immunotherapy groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy groups (general).
Study: 186417
Drug: Immunotherapy groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy groups (large-cell anaplastic carcinoma).
Study: 186417
Drug: Immunotherapy groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy groups (small-cell anaplastic carcinoma).
Study: 20095330
Drug: VitB2 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: VitB2 5 mg, VitC 200 mg, GPC capsule 50 mg, once every other day and VitA capsules 25,000 units weekly during sea-voyage
Study: 21679264
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg/day)
Study: 11707638
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (education and relaxation)
Study: 9141923
Drug: ORG 9487
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG 9487 (1.5-2.0 mg/kg)
Study: 7702805
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium diet (20 mmol) with insulin dose of 0.8 mU/min
Study: 3124676
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 10 micrograms.kg-1.h-1 naloxone after a 400 micrograms bolus (group F + N)
Study: 24529119
Drug: Usual salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual salt diet (9 g/day)
Study: 27541373
Drug: HPV-16/18 AS04-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16/18 AS04-adjuvanted vaccine
Study: 17414241
Drug: IM lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IM lorazepam 2 mg
Study: 17414241
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active treatments (IM aripiprazole 9.75 mg, 15 mg, IM lorazepam)
Study: 2649413
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of hyoscine intravenously before acid infusion
Study: 861131
Drug: Labetalol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (400 mg)
Study: 31525451
Drug: Mechanical debridement
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical debridement with adjunct antimicrobial photodynamic therapy (MD + aPDT)
Study: 27597661
Drug: MyoSure Lite
Normalized name: Lite 'N Foamy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MyoSure Lite (ML)
Study: 17299471
Drug: Oral methionine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methionine (0.17 mmol/kg body weight) with oral iron (ferrous sulfate, 13 mumol/kg)
Study: 17299471
Drug: Oral methionine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methionine (0.17 mmol/kg body weight) without oral iron
Study: 11607883
Drug: SRL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRL treatment (30 mg every 14 days for 3 months, then every 10 days until 6 months)